Maura Sonego
Aviano, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
CDK12/13 inhibition overcomes platinum resistance by impairing RNA metabolism.
Journal: Signal transduction and targeted therapy
Published: January 20, 2026
Dual inhibition of mTOR and HSP90 enhances cisplatin efficacy and overcomes resistance in ovarian cancer.
Journal: Cell death & disease
Published: August 01, 2025
USP1 deubiquitinates PARP1 to regulate its trapping and PARylation activity.
Journal: Science advances
Published: November 13, 2024
Platinum-induced upregulation of ITGA6 promotes chemoresistance and spreading in ovarian cancer.
Journal: EMBO molecular medicine
Published: July 03, 2023
Editorial: New strategies to tackle chemoresistance in cancer.
Journal: Frontiers in oncology
Published: October 06, 2022
CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review.
Journal: Frontiers in oncology
Published: March 07, 2022
HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer.
Journal: Molecular oncology
Published: September 23, 2020
A new role for IDH1 in the control of ovarian cancer cells metabolism and senescence.
Journal: Annals of translational medicine
Published: July 11, 2020
CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer.
Journal: The Journal of pathology
Published: May 22, 2020
Serum- and glucocorticoid- inducible kinase 2, SGK2, is a novel autophagy regulator and modulates platinum drugs response in cancer cells.
Journal: Oncogene
Published: December 30, 2019
Last Updated: 09/26/2026